Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Qum (Jul 2016)

Prediction of New Diagnostic and Therapeutic Approaches in Pulmonary Arterial Hypertension by Systems Biology Metho

  • Ali Salari,
  • Fatemeh Salarian

Journal volume & issue
Vol. 10, no. 5
pp. 9 – 20

Abstract

Read online

Background and Objectives: The pulmonary arterial hypertension is a narrow vessel disease, which is associated with hypertension and arterial stenosis and, finally, disorder of the right ventricle. This study was conducted with the purpose of finding new diagnostic and therapeutic approaches in pulmonary arterial hypertension using different systems biology and bioinformatics methods. Methods: In this study, microarray data of two groups (normal group as the control and pulmonary arterial hypertension as the treatment group), were compared using GEO2R software. Also, Protein kinase analysis, transcription factor analysis, protein-protein interactions, microRNA, and pharmaceutical analyzes, were performed on two sets of differential genes using KEA, ChEA, Genes2 Networks, Target Scan microRNAs, and Connectivity Map (CMAP) databases. software respectively. Finally, the protein network of differential genes of pulmonary arterial hypertension was mapped using the obtained date. Results: SUZ12 and SP1 transcription factors and MYC transcription factor were, respectively, predicted and reported as the important transcription factors of up-regulated and down-regulated genes. Moreover, PAK3 and IRAK3 were reported as the kinases of up-regulated genes and down-regulated genes, respectively, and PAK3 as a rapid diagnosis and therapeutic candidate. Briefly, Prostaglandin J2 (PGJ2) at a dose of 0.00001 M every 6 hours, and microRNAs miR-144 and miR-501 were predicted as suppressor of up-regulated genes of pulmonary arterial hypertension and reported as a therapeutic candidate. Conclusion: Application of systems biology methods could show a path towards diagnosis and treatment of pulmonary arterial hypertension using PAK3 marker, miR-144, and miR-501, and Prostaglandin J2 drug.

Keywords